EBITDA: Income before interest, taxes, depreciation and amortization.
Interpace Biosciences, Inc. (IDXG) had EBITDA of $4.96M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$38.73M |
|
$24.57M |
|
$14.60M |
|
$24.13M |
|
$34.64M |
|
$4.08M |
|
$-0.31M |
|
$3.77M |
|
$3.77M |
|
$24.98M |
|
$24.98M |
|
$24.57M |
|
$24.98M |
|
$4.08M |
|
|
EBITDA |
$4.96M |
4.42M |
|
27.70M |
|
$5.55 |
|
$0.89 |
|
| Balance Sheet Financials | |
$9.90M |
|
$1.42M |
|
$23.94M |
|
$33.84M |
|
$5.10M |
|
-- |
|
$6.37M |
|
$11.47M |
|
$22.36M |
|
$22.36M |
|
$22.36M |
|
4.43M |
|
| Cash Flow Statement Financials | |
$5.83M |
|
$-0.36M |
|
$-4.43M |
|
$1.46M |
|
$2.50M |
|
$1.04M |
|
$0.04M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.94 |
|
-- |
|
-- |
|
-- |
|
-- |
|
62.31% |
|
10.55% |
|
10.55% |
|
12.81% |
|
9.74% |
|
63.46% |
|
$5.47M |
|
-- |
|
-- |
|
-- |
|
1.14 |
|
-- |
|
6.86 |
|
53.24 |
|
111.72% |
|
111.72% |
|
73.83% |
|
111.72% |
|
$5.05 |
|
$0.20 |
|
$0.21 |
|